Meta Platforms
META
Alphabet-C
GOOG
Alphabet-A
GOOGL
Vale SA
VALE
Coinbase
COIN
US Stock MarketDetailed Quotes
COCP Cocrystal Pharma
- 2.1113
- +0.0273+1.31%
Close Jan 24 16:00 ET
- 2.0155
- -0.0958-4.54%
Post 16:28 ET
21.48MMarket Cap-1.15P/E (TTM)
2.1113High2.0100Low11.96KVolume2.0900Open2.0840Pre Close24.76KTurnover0.17%Turnover RatioLossP/E (Static)10.17MShares3.260052wk High1.69P/B14.81MFloat Cap1.325052wk Low--Dividend TTM7.01MShs Float77.4000Historical High--Div YieldTTM4.86%Amplitude1.3250Historical Low2.0700Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Cocrystal Pharma Stock Forum
Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections
Wednesday, 8th January at 8:00 am
• Data show favorable safety and tolerability with dosing up to 800 mg for 10 days
• Plans to initiate human challenge study in 2025 in norovirus-infected subjects
BOTHELL, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP) ("Cocry...
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor
Cocrystal Pharma (Nasdaq: COCP) reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of its Phase 1 study for CDI-988, an oral pan-viral norovirus/coronavirus protease inhibitor.
The study, conducted in Australia, evaluated doses ranging from 100 mg to 60...
NEWS
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
$AeroClean Technologies (AERC.US)$ $Bit Brother (BTB.US)$ $Cocrystal Pharma (COCP.US)$ $FingerMotion (FNGR.US)$ $GLOBAL TECH INDUSTRIES GROUP INC (GTII.US)$ $Home Depot (HD.US)$ $Oncternal Therapeutics (ONCT.US)$ $Pinterest (PINS.US)$ $Rivian Automotive (RIVN.US)$ $Snap Inc (SNAP.US)$ $SOBR Safe (SOBR.US)$ $Twitter (Delisted) (TWTR.US)$
No comment yet